This study compared the course of coronavirus disease 2019 (COVID-19) in vaccinated and unvaccinated patients admitted to an intensive care unit (ICU) and evaluated the effect of vaccination with CoronaVac on admission to ICU. Patients admitted to ICU due to COVID-19 between 1 April 2021 and 15 May 2021 were enrolled to the study. Clinical, laboratory, radiological parameters, hospital and ICU mortality were compared between vaccinated patients and eligible but unvaccinated patients. Patients over 65 years old were the target population of the study due to the national vaccination schedule. Data from 90 patients were evaluated. Of these, 36 (40.0%) were vaccinated. All patients had the CoronaVac vaccine. Lactate dehydrogenase and ferritin levels were higher in an unvaccinated group than vaccinated group ( P = 0.021 and 0.008, respectively). SpO 2 from the first arterial blood gas at ICU was 83.71 ± 19.50% in vaccinated, 92.36 ± 6.59% in unvaccinated patients ( P = 0.003). Length of ICU and hospital stay were not different ( P = 0.204, 0.092, respectively). ICU and hospital mortality were similar between groups ( P = 0.11 and 0.70, respectively). CoronaVac vaccine had no effect on survival from COVID-19. CoronaVac’s protective effect, especially on new genetic variants, should be investigated further.
【저자키워드】 COVID-19, vaccination, SARS-CoV-2 pandemic, CoronaVac, Sinovac, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, Vaccine, Mortality, intensive care, hospital, intensive care unit, CoronaVac, ferritin, lactate dehydrogenase, ICU, Laboratory, Hospital mortality, survival, clinical, Patient, genetic variants, group, Admission, parameters, patients, Blood, protective effect, Lactate, Hospital stay, no effect, on admission, arterial blood, target population, arterial blood gas, blood gas, ferritin levels, Radiological parameters, National, vaccination schedule, radiological, Course, enrolled, investigated, evaluated, had no, not different, Length, admitted to ICU, eligible, ferritin level, 【제목키워드】 intensive care, SARS-CoV-2 vaccine, survival, inactivated,